A top London-based British American Tobacco (BAT) making brand claimed that it had developed an experimental coronavirus vaccine and it is ready for a human trial on Friday.
The company in a statement said, “Pre-clinical tests of the vaccine showed a positive immune response. The first phase of human trials could begin as soon as late June if authorized by drug regulators”.
Making a COVID-19 vaccine using tobacco plants stands in stark contrast to the effects of other related products on health. Smoking cigarettes may raise the risk of severe coronavirus symptoms, according to the World Health Organization(WHO). British American Tobacco is the world’s No. 2 manufacturer of cigarettes, the leading cause of lung cancer across the world.
In April, BAT announced that its biotech subsidiary, Kentucky Bio Processing (KBP), was developing a potential vaccine for COVID-19. Since then, we have been completing preclinical testing and are pleased to report the potential vaccine has been shown to produce a positive immune response,” BAT stated.
COVID-19: I am opposed to vaccination, says Djokovic
BAT subsidiary Kentucky Bioprocessing is utilizing tobacco vegetation to make experimental vaccines. BAT says that this vaccine is being manufactured quickly. However, vaccination of the coronavirus utilizing tobacco vegetation can have completely different results on well being than others.
The coronavirus, which originated in the town of Wuhan, China took over the whole world killing lakhs of people. The only way to wash off this deadly virus from the Earth is an antidote. Several analysis institutes and firms are engaged in growing a vaccine for the lethal virus. BAT additionally listed its efforts in several international locations in the struggle against coronavirus. In the United Kindom, the cigarette maker is offering tools to be used in COVID-19 testing centers.
